Press release
Vitiligo Competitive Landscape 2025: Clinical Trial Analysis, Therapies, FDA Approvals, Future Outlook by DelveInsight
Vitiligo Competitive Landscape
As per DelveInsight's evaluation, the global Vitiligo treatment pipeline features 20+ leading companies actively engaged in developing 20+ therapeutic candidates. The analysis covers Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and developmental updates.
The Vitiligo Pipeline report offers extensive commercial and clinical insight into pipeline assets spanning from the preclinical stage to marketed products. It provides a comprehensive overview of each drug, detailing mechanism of action, clinical progress, NDA submissions (if applicable), and product development efforts such as technological platforms, partnerships, mergers and acquisitions, funding initiatives, regulatory designations, and related updates.
Download sample report to get detailed insights in the Vitiligo pipeline landscape - https://www.delveinsight.com/sample-request/vitiligo-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the major highlights from the Vitiligo Pipeline Report:
• Organizations across the globe are persistently advancing innovative therapies for Vitiligo, showing notable success over time.
• Companies involved in the Vitiligo treatment landscape include Clinuvel Pharmaceuticals, Bioniz Therapeutics, TAGCyx Biotechnologies, Temprian Therapeutics, Aclaris Therapeutics, TWi Biotechnology, Dermavant Science, Amgen, Pfizer, Incyte Corporation, Clinuvel Pharmaceuticals, among others.
• Prominent emerging therapies in various stages of clinical development include Phimelanotide, BNZ-1, TAGX-0003, TT-01, ATI-1777, AC-1101, Cerdulatinib, AMG 714, Ritlecitinib, Ruxolitinib, Afamelanotide, Crisaborole 2% Topical Ointment, and additional assets anticipated to influence the Vitiligo market in the coming years.
• In March 2025, STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company focused on advanced dermatologic treatments, announced results from a newly published study in Japan. The findings underscore the advantages of high repetition rate, high dose, coherent collimated narrow band Excimer Laser technology over other UVB light options, which lack the precision and fluence seen with Excimer Light for conditions such as Vitiligo, Psoriasis, Alopecia Areata, and Atopic Dermatitis.
• In February 2025, Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical firm focused on host-directed therapies for immuno-inflammatory disorders, reported its financial results for Q4 ending December 31, 2024, along with corporate developments. Progress was highlighted on EB06, an anti-CXCL10 monoclonal antibody intended to deliver durable therapeutic benefit for vitiligo.
• In January 2025, VYNE Therapeutics completed patient enrollment in its Phase IIb randomized clinical study evaluating VYN201 gel (repibresib) for non-segmental vitiligo. The double-blind, vehicle-controlled trial is assessing safety, pharmacokinetics, and efficacy of once-daily gel application at 1%, 2%, and 3% concentrations versus vehicle.
• In May 2024, Edesa Biotech, Inc. (NASDAQ: EDSA) prepared to initiate a Phase 2 trial of its anti-CXCL10 monoclonal antibody for moderate-to-severe non-segmental vitiligo. This type of vitiligo involves symmetric depigmented patches triggered by autoimmune reactions, genetics, or external stressors such as sunburn or trauma.
Vitiligo Overview
Vitiligo is a long-term dermatological condition in which melanin-producing cells (melanocytes) are destroyed or cease functioning, leading to loss of skin color. White patches may appear on the skin, hair, and, in some instances, inside the mouth or eyes.
Request a Free Sample PDF Report to explore Vitiligo Pipeline Therapeutic Assessment:
https://www.delveinsight.com/report-store/vitiligo-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Emerging Vitiligo Drugs Across Clinical Development Phases:
• Phimelanotide: Clinuvel Pharmaceuticals
• BNZ-1: Bioniz Therapeutics
• TAGX-0003: TAGCyx Biotechnologies
• TT-01: Temprian Therapeutics
• ATI-1777: Aclaris Therapeutics
• AC-1101: TWi Biotechnology
• Cerdulatinib: Dermavant Science
• AMG 714: Amgen
• Ritlecitinib: Pfizer
• Ruxolitinib: Incyte Corporation
• Afamelanotide: Clinuvel Pharmaceuticals Limited
• Crisaborole 2% Topical Ointment: Pfizer
Vitiligo Route of Administration
The pipeline evaluation categorizes therapies by various ROAs, including:
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
Vitiligo Molecule Type
Pipeline therapies are segmented by molecule category, including:
• Monoclonal Antibody
• Peptides
• Polymer
• Small Molecule
• Gene Therapy
Vitiligo Pipeline Therapeutics Assessment
• Vitiligo Assessment by Product Type
• Vitiligo By Stage and Product Type
• Vitiligo Assessment by Route of Administration
• Vitiligo By Stage and Route of Administration
• Vitiligo Assessment by Molecule Type
• Vitiligo By Stage and Molecule Type
DelveInsight's Vitiligo Report includes around 20+ products across multiple stages such as:
• Phase III (Late-stage)
• Phase II (Mid-stage)
• Phase I (Early-stage)
• Pre-clinical & Discovery candidates
• Discontinued & Inactive programs
• Route of Administration
Further details on Vitiligo products are provided in the full report. Download the Vitiligo pipeline report to gain deeper insights into emerging therapies:
https://www.delveinsight.com/sample-request/vitiligo-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Companies in the Vitiligo Therapeutics Landscape:
Notable players include Dermavant Sciences, Incyte Corporation, TWi Biotechnology, Aclaris Therapeutics, Dermira, Amgen, Pfizer, Arcutis Biotherapeutics, AnaptysBio, Bioniz Therapeutics, and others.
Vitiligo Pipeline Analysis Includes:
• Comprehensive insights into companies developing Vitiligo treatments and the number of assets per company.
• Segmentation of pipeline candidates into early-stage, mid-stage, and late-stage development.
• Active and discontinued therapeutic projects by key market participants.
• Assessment of investigational drugs by stage, ROA, monotherapy/combination therapy, receptor targets, mechanism of action, and molecular type.
• Detailed review of strategic collaborations (industry-industry and industry-academia), licensing agreements, and financing activities supporting market advancement.
The analysis is based on DelveInsight's proprietary databases, company/university sites, clinical trial records, conference material, investor presentations, SEC filings, and verified press releases from third-party industry sources.
Download the Sample PDF Report for comprehensive insights on Vitiligo therapies:
https://www.delveinsight.com/sample-request/vitiligo-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Vitiligo Pipeline Market Drivers
• Growing disease awareness, high unmet needs, expanding patient base, and improved healthcare infrastructure are key contributors to Vitiligo market growth.
Vitiligo Pipeline Market Challenges
• Long-term treatment requirements, adherence issues, limited financial support, stringent regulatory pathways, and other constraints continue to hinder market expansion.
Scope of Vitiligo Pipeline Drug Insight
• Coverage: Global
• Key Companies: Clinuvel Pharmaceuticals, Bioniz Therapeutics, TAGCyx Biotechnologies, Temprian Therapeutics, Aclaris Therapeutics, TWi Biotechnology, Dermavant Science, Amgen, Pfizer, Incyte Corporation, Clinuvel Pharmaceuticals, among others
• Major Therapies: Phimelanotide, BNZ-1, TAGX-0003, TT-01, ATI-1777, AC-1101, Cerdulatinib, AMG 714, Ritlecitinib, Ruxolitinib, Afamelanotide, Crisaborole 2% Topical Ointment, and more
• Therapeutic Scope: Current marketed products and emerging Vitiligo treatments
• Market Dynamics: Vitiligo drivers and Vitiligo barriers
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Vitiligo Competitive Landscape 2025: Clinical Trial Analysis, Therapies, FDA Approvals, Future Outlook by DelveInsight here
News-ID: 4226181 • Views: …
More Releases from DelveInsight Business Research
Myelodysplastic Syndrome Competitive Landscape 2025: Clinical Trial Analysis, Th …
DelveInsight's, "Myelodysplastic Syndrome Pipeline Insight 2025" report provides comprehensive insights about 120+ companies and 150+ pipeline drugs in Myelodysplastic Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Myelodysplastic Syndrome Pipeline Report
• DelveInsight's Myelodysplastic Syndrome…
Fibromyalgia Competitive Landscape 2025: Clinical Trial Analysis, Therapies, FDA …
According to DelveInsight, the global Fibromyalgia pipeline features more than eight key companies actively developing over ten treatment candidates. The analysis encompasses ongoing clinical trials, therapeutic mechanisms of action, routes of administration, and recent developments within the Fibromyalgia treatment landscape.
The Fibromyalgia Pipeline 2025 report provides an exhaustive evaluation of pipeline products, ranging from preclinical stages to marketed therapies. It includes comprehensive details on each drug's mechanism of action, clinical trial…
Chronic Wounds Competitive Landscape 2025: Clinical Trial Analysis, Therapies, F …
As per DelveInsight's assessment, globally, Chronic Wounds pipeline constitutes 7+ key companies continuously working towards developing 8+ Chronic Wounds treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Chronic Wounds Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Wounds Market.
The Chronic Wounds Pipeline report embraces in-depth commercial and clinical assessment…
Global Medical Device Contract Manufacturing Market to Witness ~12% CAGR by 2032 …
DelveInsight's Medical Device Contract Manufacturing Market Insights report delivers a detailed evaluation of the current and projected global market for medical device contract manufacturing. The report examines the market shares of leading companies, growth drivers, barriers, market trends, and emerging opportunities, providing a holistic understanding of the competitive landscape.
The market is currently witnessing robust growth due to rising demand for sophisticated yet cost-effective medical devices. Contributing factors include the increasing…
More Releases for Vitiligo
Organic Care Australia Introduces 'Vitiligo Organics' - A Revolutionary Herbal T …
Image: https://www.getnews.info/uploads/39ec7fd227c4937add1acccc27f32c1b.jpg
Organic Care Australia proudly announced the launch of 'Vitiligo Organics' in 2009, a revolutionary herbal treatment that promises new hope for individuals living with vitiligo, a condition characterized by the loss of skin pigmentation resulting in white patches. This innovative product represents a significant breakthrough in the management of vitiligo, offering a natural, effective solution for those who have long sought an alternative to conventional treatments.
Vitiligo impacts millions worldwide,…
Vitiligo Treatment Market - Unleash Your True Colors: Breakthrough Vitiligo Trea …
Newark, New Castle, USA: The "Vitiligo Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Vitiligo Treatment Market: https://www.growthplusreports.com/report/vitiligo-treatment-market/7780
This latest report researches the industry structure, sales, revenue,…
Vitiligo - Drug Pipeline Landscape, 2022
Vitiligo is a chronic disorder that causes patches of skin to lose pigment or color, when melanocytes are attacked and destroyed, causing the skin to turn a milky-white color. There are two types of vitiligo such as nonsegmental or generalized vitiligo and segmental vitiligo. Nonsegmental or generalized vitiligo happens when the white patches appear symmetrically on both sides of body, such as on both hands or both knees. Segmental vitiligo…
Vitiligo Treatment Market: Rising Impressive Business Opportunities Analysis For …
Vitiligo Treatment Market Report 2022: Industry aims to provide an overview of the industry through detailed market segmentation. The report offers thorough information about the overview and scope of the market along with its drivers, restraints, and trends. This report is designed to include both qualitative and quantitative aspects of the industry in each region and country participating in the study.
Get a Sample PDF of the Report @ https://impeccablemarketresearch.com/enquiry/request-sample-pdf/14636671?utm_source=Openpr&utm_medium=Shubhamko
…
Vitiligo Skin Disorder
Vitiligo Skin Disorder
Vitiligo skin disorder is a skin condition in which white patches on the skin are formed due to malfunctioning of melanocytes, cells that promote pigmentation. http://www.curevitiligooil.com/Vitiligo-Skin-Disorder.htmlThe start of this disease and the grimness of pigment loss vary from person to person. People who have light skin usually witness the loss of pigment in summers because the contrast between depigmented skin and sunburned skin appears distinctive. On the other…
Vitiligo Symptoms
Vitiligo produces macules which are small areas of different skin color. The skin disorder may also produce patches which are flat, pale or white and can't be felt with fingers. (http://www.curevitiligooil.com/Vitiligo-Symptoms.html). These marks frequently expand to form very large, irregularly-shaped areas with no pigmentation. Typically, these are painless and do not itch. The cause of vitiligo symptoms is not known, but autoimmunity may be a factor. Since it is a…
